UBS Reaffirms Their Buy Rating on Neurocrine (NBIX)
In a report released today, Ashwani Verma from UBS maintained a Buy rating on Neurocrine, with a price target of $178.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Verma covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Insmed, and Neurocrine. According to TipRanks, Verma has an average return of 12.5% and a 55.00% success rate on recommended stocks.
In addition to UBS, Neurocrine also received a Buy from TipRanks – xAI’s xAi Drug Manufacturers – Specialty and Generic in a report issued yesterday. However, on January 8, Morgan Stanley downgraded Neurocrine (NASDAQ: NBIX) to a Hold.
Based on Neurocrine’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $794.9 million and a net profit of $209.5 million. In comparison, last year the company earned a revenue of $622.1 million and had a net profit of $129.8 million
Read More on NBIX:
Disclaimer & DisclosureReport an Issue
- Neurocrine price target lowered to $178 from $188 at UBS
- Neurocrine’s Ingrezza capsules show efficacy in involuntary movement disorders
- Neurocrine price target lowered to $177 from $179 at JPMorgan
- Neurocrine price target lowered to $169 from $172 at Truist
- Neurocrine downgraded to Equal Weight from Overweight at Morgan Stanley
